Sight Sciences developing eyecare technologies for glaucoma and dry eye disease, reporting financial results.

From GlobeNewswire: 2024-07-18 16:05:00

Sight Sciences, Inc. will report financial results for the second quarter on August 1, 2024. The Company is focused on developing innovative eyecare technologies to enhance patient care. Their OMNI® Surgical System targets glaucoma, the leading cause of irreversible blindness, while the TearCare® System addresses evaporative dry eye disease. Investors can access a live and archived webcast of the event.

Sight Sciences aims to transform eyecare with minimally invasive solutions for prevalent eye diseases. Their OMNI® Surgical System is designed to reduce intraocular pressure in adults with glaucoma and is CE Marked for use in Europe. The TearCare® System offers localized heat therapy for evaporative dry eye disease. Glaucoma is the main cause of irreversible blindness.

The Company’s innovations, including the OMNI® Surgical System and the TearCare® System, target prevalent eye diseases like glaucoma and evaporative dry eye disease. These technologies offer minimally invasive treatment options to improve patient care. Glaucoma is the world’s leading cause of irreversible blindness.

Sight Sciences is focused on developing and commercializing interventional solutions to transform eyecare. Their OMNI® Surgical System is indicated for reducing intraocular pressure in adults with glaucoma, while the TearCare® System offers localized heat therapy for evaporative dry eye disease. Glaucoma is the world’s leading cause of irreversible blindness.



Read more at GlobeNewswire:: Sight Sciences to Report Second Quarter Financial Results